



Katherine “Katie” Rubino

PARTNER

krubino@wiggin.com

Boston: +1 857 491 9647

Katie Rubino is a Partner in the Corporate Department.

Katie frequently represents clients on target discovery collaborations, assisting in structuring spin-offs, divestitures, and out-licensing from pharma, hospital systems, and academic research institutions. She also counsels life sciences companies developing pharmaceuticals, vaccines, antibody products, digital health, medical devices, artificial intelligence, and quantum computing, and advises companies raising growth capital, merger and acquisition transactions, and initial public offerings. Katie is experienced in transactions involving intellectual property rights, strategic partnerships, licensing, and research collaborations.

Katie is active in industry organizations and chairs the American Chemical Society’s Chemistry and the Law Division. She speaks frequently on intellectual property and life sciences at MIT, Harvard, Yale, and Northeastern, and has been featured in *The Wall Street Journal*, Fox Business, and Corporate Compliance Insights. She co-authored *You Are an IP Company: The 12-Step Plan to Increase Your Intellectual Property Influence, Impact, and Income* and co-hosts the *You Are an IP Company podcast* (Apple Podcasts, Spotify, and YouTube).

Katie holds a J.D. from Suffolk University Law School, a Doctor of Pharmacy from Northeastern University, and is dually qualified to practice in both the United States and England and Wales.

Education

- Suffolk University Law School (J.D.)
 - Cum Laude, Concentration in Intellectual Property Law with Distinction
- Northeastern University (PharmD)
- Northeastern University (B.S.)
 - Magna Cum Laude

Bar Admissions

- England and Wales
- District of Columbia
- Massachusetts
- U.S. Patent and Trademark Office

Court Admissions

- US Court of Appeals for the Federal Circuit

Publications

June 25, 2026

Skinny Labels, Big Stakes for Pharmaceuticals: The Supreme Court's Hikma v. Amarin Decision

April 30, 2026

Wiggin and Dana's Life Science Team authors the Massachusetts chapter for Chambers Life Sciences 2026: A Chambers Global Practice Guide

Chambers Global Practices Guides

April 10, 2026

Key Patent Issues for Foreign Companies to Consider Before Entry into the U.S. Market; Part II

March 11, 2026

Seven Reasons Why Third-Party Funders Decline to Fund Patent Cases

March 6, 2026

AI Is Transforming Life Sciences. The Oversight Structures Are Still Catching Up.

Corporate Compliance Insights

March 4, 2026

Key Patent Issues for Foreign Companies to Consider Before Entry into the U.S. Market

November 4, 2025

Beyond the Secret Sauce: Turning IP Into Acquisition Leverage

Corporate Compliance Insights

October 31, 2025

Rail Yard Automation Patents Derailed at Delaware District Court

October 7, 2025

A Recipe for Invalidation: Food Delivery Comparison Patents Found Ineligible Under § 101

September 26, 2025

NIH Announces New Application Structure for NIH-Funded International Collaborations That Eliminates Foreign Subawards

August 21, 2025

Accessing U.S. Capital Markets

November 1, 2024

You Are an IP Company: The 12-Step Plan to Increase Your Intellectual Property Influence, Impact, and Income

Ethos Collective